The Leukemia & Lymphoma Society of Canada is actively monitoring the prioritization of COVID-19 vaccinations for people affected by blood cancers. The situation is in flux as provinces are revisiting and, in some cases, amending their priority access recommendations for vulnerable populations.

Newfoundland & Labrador, New Brunswick, Prince Edward Island, Ontario and British Columbia have prioritized vaccinations in the April – June timeframe for defined vulnerable populations. Given the evolving nature of this process across provincial health authorities, LLSC will continue to closely monitor changes in priority status as we enter into the next phase of vaccinations to ensure equitable access for all people affected by blood cancers across Canada.

While the COVID-19 vaccines are approved for general use, people with cancer and compromised immune systems were not included in the COVID-19 vaccine clinical trials. This vulnerable population is believed to be at greater risk of serious complications should they contract the virus which is why Health Canada advises that people affected by blood cancers consult with their attending physician before being vaccinated. 

The Leukemia & Lymphoma Society of Canada is committed to supporting and advocating for the blood cancer community and will continue to monitor the rollout of COVID-19 vaccinations.